Flow Neuroscience Series A

Flow Neuroscience offers the Flow FL-100, the first and only FDA-approved at-home transcranial direct current stimulation (tDCS) treatment for adults aged 18 and older with moderate to severe Major Depressive Disorder. This neuromodulation treatment can be used as a standalone therapy or as an adjunct to antidepressant medication, with US availability expected in summer 2026. The company highlights its product's favorable safety profile and potential to reduce suicidal ideation and avoid psychiatric hospital admissions.